Quantitative approaches to drug development
We provide consultancy services to help our clients reduce uncertainty in research and regulatory questions, increasing confidence in the development of new medicines that can improve patients’ lives. Science and Services
About
Pharmetheus reduces uncertainty in all phases of drug development.
Featured content
This new work explore the distinction between conditional and unconditional covariate effects, an important nuance when models include correlated predictors like body weight and age. This work provides a framework to improve the clarity of dosing recommendations, ensuring they are robust and actionable for prescribers across diverse patient populations.
Phase I studies are increasingly used to assess drug QT liability, however early-phase trials often lack the strict controls for meal intake and sampling times found in dedicated “thorough QT” (TQT) studies. Without such standardization, significant variability can be introduced, potentially masking or exaggerating the perceived proarrhythmic risk.
This work offers a standardized method that lets developers generate reliable PK predictions early in development. By using a reference ‘Kd FcRn value’ the industry can move from the lab to the clinic faster, with greater confidence and less reliance on animal testing.
How we work
Traceability, accountability, and independent quality control are of utmost importance to us, and embedded in our way of working.
Publications
Explore our scientific publications.
Explore our web
Model-Informed Drug Development (MIDD) consulting services
A quantitative framework to support and inform development program strategies and decisions.
“Sharing with colleagues is why I love working here”
Sophie Peigné supports clients with expert and strategic advice in pharmacometrics as well as hands-on modeling analyses for compounds in all development phases.
History of Pharmetheus
Our journey is an exciting one. We began as a start-up that spinned off from Uppsala University. Today, we have grown into a global medium-sized company, adding value to drug development each day.